PLX-4720

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H14ClF2N3O3S
Molecular Weight	413.826
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(Cl)C=C23)=C1F

InChI

InChIKey=YZDJQTHVDDOVHR-UHFFFAOYSA-N

InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula	C17H14ClF2N3O3S
Molecular Weight	413.826
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21355020 | https://www.ncbi.nlm.nih.gov/pubmed/18287029

PLX-4720 is a pre-clinical analog of vemurafenib which selectively targets BRAFV600E. PLX-4720 was developed by Plexxikon for the treatment of thyroid cancer, however the drug did not reach clinical phase.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
RAF serine/threonine protein kinase 1 Target ID: CHEMBL3559685 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18287029	Inhibitor 8504		13.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Thyroid cancer 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21355020	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Comprehensive analysis of kinase inhibitor selectivity.	2011-10-30	22037378
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.	2010-11-24	21095574
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.	2008-02-26	18287029
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.	2003-01	12538485

Patents

Sample Use Guides

In Vivo Use Guide

Mice were given PLX-4720 at a dose of 30 mg/kg/day.

Route of Administration: Oral

In Vitro Use Guide

Human thyroid carcinoma cell lines 8505c, TPC-1, and NT cells were treated with 1 or 10 uM of PLX-4720 during 72 hours. At 1 uM the drug caused significant reduction in cell prolifiration.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:57:29 GMT 2025` Edited by `admin` on `Mon Mar 31 22:57:29 GMT 2025`
Record UNII	EQY31RO8HA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1-PROPANESULFONAMIDE, N-(3-((5-CHLORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)CARBONYL)-2,4-DIFLUOROPHENYL)-

Preferred Name

English

PLX-4720

Common Name

English

Code System Code Type Description

FDA UNII

EQY31RO8HA